Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 138

1.

Impact of Delayed Appropriate Antibiotic Therapy on Patient Outcomes by Antibiotic Resistance Status From Serious Gram-negative Bacterial Infections.

Bonine NG, Berger A, Altincatal A, Wang R, Bhagnani T, Gillard P, Lodise T.

Am J Med Sci. 2019 Feb;357(2):103-110. doi: 10.1016/j.amjms.2018.11.009. Epub 2018 Nov 22.

PMID:
30665490
2.

Development and Assessment of Risk Scores for Carbapenem and Extensive β-Lactam Resistance Among Adult Hospitalized Patients With Pseudomonas aeruginosa Infection.

Tartof SY, Kuntz JL, Chen LH, Wei R, Puzniak L, Tian Y, Im TM, Takhar HS, Merchant S, Lodise T.

JAMA Netw Open. 2018 Oct 5;1(6):e183927. doi: 10.1001/jamanetworkopen.2018.3927.

PMID:
30646267
3.

Myelosuppression with Oxazolidinones: Are There Differences?

Hardalo C, Lodise TP, De Anda C.

Antimicrob Agents Chemother. 2018 Dec 21;63(1). pii: e01833-18. doi: 10.1128/AAC.01833-18. Print 2019 Jan. No abstract available.

PMID:
30578404
4.

Antimicrobial Susceptibility Trends Observed in Urinary Pathogens Obtained From New York State.

Rank EL, Lodise T, Avery L, Bankert E, Dobson E, Dumyati G, Hassett S, Keller M, Pearsall M, Lubowski T, Carreno JJ.

Open Forum Infect Dis. 2018 Nov 16;5(11):ofy297. doi: 10.1093/ofid/ofy297. eCollection 2018 Nov.

5.
6.

Reappraisal of Contemporary Pharmacokinetic and Pharmacodynamic Principles for Informing Aminoglycoside Dosing.

Bland CM, Pai MP, Lodise TP.

Pharmacotherapy. 2018 Dec;38(12):1229-1238. doi: 10.1002/phar.2193.

PMID:
30403305
7.

Safety of Delafloxacin: Focus on Adverse Events of Special Interest.

Lodise T, Corey R, Hooper D, Cammarata S.

Open Forum Infect Dis. 2018 Sep 10;5(10):ofy220. doi: 10.1093/ofid/ofy220. eCollection 2018 Oct.

9.

Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help?

Crass RL, Pai MP, Lodise TP Jr.

J Antimicrob Chemother. 2019 Jan 1;74(1):126-129. doi: 10.1093/jac/dky388.

PMID:
30252050
10.
11.

Association Between Carbapenem Resistance and Mortality Among Adult, Hospitalized Patients With Serious Infections Due to Enterobacteriaceae: Results of a Systematic Literature Review and Meta-analysis.

Martin A, Fahrbach K, Zhao Q, Lodise T.

Open Forum Infect Dis. 2018 Jun 28;5(7):ofy150. doi: 10.1093/ofid/ofy150. eCollection 2018 Jul. Review.

12.

The Importance of Individualized Vancomycin Dosing to Ensure Optimal Exposure Early in Therapy.

Zasowski EJ, Lodise TP.

J Clin Pharmacol. 2018 Sep;58(9):1131-1133. doi: 10.1002/jcph.1281. Epub 2018 Jul 19. No abstract available.

PMID:
30024648
13.

A Fixed versus Weight-Based Dosing Strategy of Daptomycin May Improve Safety in Obese Adults.

Butterfield-Cowper JM, Lodise TP Jr, Pai MP.

Pharmacotherapy. 2018 Sep;38(9):981-985. doi: 10.1002/phar.2157. Epub 2018 Jul 12.

PMID:
29906315
14.

Pooled analysis of the phase 3 REVIVE trials: randomised, double-blind studies to evaluate the safety and efficacy of iclaprim versus vancomycin for treatment of acute bacterial skin and skin-structure infections.

Huang DB, Corey GR, Holland TL, Lodise T, O'Riordan W, Wilcox MH, File TM Jr, Dryden M, Balser B, Desplats E, Torres A.

Int J Antimicrob Agents. 2018 Aug;52(2):233-240. doi: 10.1016/j.ijantimicag.2018.05.012. Epub 2018 May 19.

PMID:
29783024
15.

A Phase 3, Randomized, Double-Blind, Multicenter Study To Evaluate the Safety and Efficacy of Intravenous Iclaprim versus Vancomycin for Treatment of Acute Bacterial Skin and Skin Structure Infections Suspected or Confirmed To Be Due to Gram-Positive Pathogens (REVIVE-2 Study).

Holland TL, O'Riordan W, McManus A, Shin E, Borghei A, File TM Jr, Wilcox MH, Torres A, Dryden M, Lodise T, Oguri T, Corey GR, McLeroth P, Shukla R, Huang DB.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02580-17. doi: 10.1128/AAC.02580-17. Print 2018 May.

16.

Clinical safety and tolerability of tedizolid phosphate in the treatment of acute bacterial skin and skin structure infections.

Hardalo C, Lodise TP, Bidell M, Flanagan S, De Anda C, Anuskiewicz S, Prokocimer P.

Expert Opin Drug Saf. 2018 Apr;17(4):359-367. doi: 10.1080/14740338.2018.1446939. Epub 2018 Mar 12. Review.

PMID:
29528251
17.

Effective Antimicrobial Stewardship Strategies for Cost-effective Utilization of Telavancin for the Treatment of Patients With Hospital-acquired Bacterial Pneumonia Caused by Staphylococcus aureus.

McKinnell JA, Corman S, Patel D, Leung GH, Gordon LM, Lodise TP.

Clin Ther. 2018 Mar;40(3):406-414.e2. doi: 10.1016/j.clinthera.2018.01.010. Epub 2018 Feb 15.

18.

Pharmacokinetic and Pharmacodynamic Analyses To Determine the Optimal Fixed Dosing Regimen of Iclaprim for Treatment of Patients with Serious Infections Caused by Gram-Positive Pathogens.

Lodise TP, Bosso J, Kelly C, Williams PJ, Lane JR, Huang DB.

Antimicrob Agents Chemother. 2018 Jan 25;62(2). pii: e01184-17. doi: 10.1128/AAC.01184-17. Print 2018 Feb.

19.

Determination of alternative ceftolozane/tazobactam dosing regimens for patients with infections due to Pseudomonas aeruginosa with MIC values between 4 and 32 mg/L.

Natesan S, Pai MP, Lodise TP.

J Antimicrob Chemother. 2017 Oct 1;72(10):2813-2816. doi: 10.1093/jac/dkx221.

PMID:
29091209
20.

Vancomycin Plus Piperacillin-Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-Analysis.

Luther MK, Timbrook TT, Caffrey AR, Dosa D, Lodise TP, LaPlante KL.

Crit Care Med. 2018 Jan;46(1):12-20. doi: 10.1097/CCM.0000000000002769. Review.

PMID:
29088001

Supplemental Content

Loading ...
Support Center